Safety evaluation of M9241 in combination with docetaxel in metastatic prostate cancer.Mohammad Atiq, Ravi A. Madan, Philip M. Arlen et al.|Journal of Clinical Oncology|2022Cited by 4
Combining IL-12 immunocytokine (M9241) with docetaxel in metastatic prostate cancer: A phase I study.Mohammad Atiq, Ravi A. Madan, Elias Bin Aris Chandran et al.|Journal of Clinical Oncology|2022Cited by 3
First-line pembrolizumab plus androgen deprivation therapy for locally advanced microsatellite instability-high prostate cancer in a patient with Muir-Torre syndrome: A case reportMohammad Atiq, Ravi A. Madan, Danielle M. Pastor et al.|Frontiers in Oncology|2023Cited by 1